Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

被引:0
|
作者
Andreas Soejitno
Anastasia Tjan
Thomas Eko Purwata
机构
[1] National Hospital,Department of General Medicine
[2] Siloam General Hospital,Department of General Medicine
[3] Faculty of Medicine Pelita Harapan University,Department of Neurology
[4] Sanglah General Hospital,undefined
[5] Faculty of Medicine Udayana University,undefined
来源
CNS Drugs | 2015年 / 29卷
关键词
Positron Emission Tomography; Mild Cognitive Impairment; Cerebral Amyloid Angiopathy; Target Engagement; Amyloid Precursor Protein Transgenic Mouse;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is one of the most debilitating neurodegenerative diseases and is predicted to affect 1 in 85 people by 2050. Despite much effort to discover a therapeutic strategy to prevent progression or to cure AD, to date no effective disease-modifying agent is available that can prevent, halt, or reverse the cognitive and functional decline of patients with AD. Several underlying etiologies to this failure are proposed. First, accumulating evidence from past trials suggests a preventive as opposed to therapeutic paradigm, and the precise temporal and mechanistic relationship of β-amyloid (Aβ) and tau protein should be elucidated to confirm this hypothesis. Second, we are in urgent need of revised diagnostic criteria to support future trials. Third, various technical and methodological improvements are required, based on the lessons learned from previous failed trials.
引用
收藏
页码:487 / 502
页数:15
相关论文
empty
未找到相关数据